Friedreich ataxia is the most common of the hereditary ataxias. It is due to homozygous/compound heterozygous mutations in FXN. This gene encodes frataxin, a protein largely localized to mitochondria. In about 96% of affected individuals there is homozygosity for a GAA repeat expansion in intron 1 of the FXN gene. Studies of people with Friedreich ataxia and of animal and cell models, have provided much insight into the pathogenesis of this disorder. The expanded GAA repeat leads to transcriptional deficiency of the FXN gene. The consequent deficiency of frataxin protein leads to reduced iron-sulfur cluster biogenesis and mitochondrial ATP production, elevated mitochondrial iron, and oxidative stress. More recently, a role for inflammation has emerged as being important in the pathogenesis of Friedreich ataxia. These findings have led to a number of potential therapies that have been subjected to clinical trials or are being developed toward human studies. Therapies that have been proposed include pharmaceuticals that increase frataxin levels, protein and gene replacement therapies, antioxidants, iron chelators and modulators of inflammation. Whilst no therapies have yet been approved for Friedreich ataxia, there is much optimism that the advances in the understanding of the pathogenesis of this disorder since the discovery its genetic basis, will result in approved disease modifying therapies in the near future.
Introduction
Friedreich ataxia (FRDA) is the most common inherited ataxia among those of European ancestry with approximately 1 in 40,000 people affected (Cossee et al., 1997) . With an average age of onset of 10-15 years, FRDA causes progressive ataxia of limbs and gait, dysarthria, cardiomyopathy and an increased rate of diabetes mellitus (Delatycki and Corben, 2012) . People with FRDA become increasingly dependent on others for activities of daily living. Wheelchair use is necessary on average 15 years after symptom onset. Lifespan is markedly reduced with the average time from onset to death being 36 years (De Michele et al., 1996) . The most common cause of death is complications of cardiomyopathy (Tsou et al., 2011) .
The main sites of neuropathology in FRDA are the dorsal root ganglia, dentate nuclei of the cerebellum, posterior columns, spinocerebellar tracts and corticospinal tracts of the spinal cord and peripheral nerves (Koeppen, 2011) . The heart and pancreas are other major sites of FRDA-related pathology.
The genetic cause of FRDA was identified in 1996 as homozygous/ compound heterozygous mutations in FXN (previously called X25 and FRDA) (Campuzano et al., 1996) . Approximately 96% of affected individuals are homozygous for an expanded GAA trinucleotide repeat in intron 1 of FXN with the remaining 4% being compound heterozygous for a GAA expansion in one allele and a different pathogenic mutation in the other allele (Galea et al., 2016) . Normally there are fewer than 36 GAA repeats whilst those affected have between 56 and about 1300 repeats. There is an inverse correlation between the number of GAA repeats in the smaller allele (GAA1) and age of symptom onset and some complications including the presence of cardiomyopathy, diabetes mellitus, scoliosis and time from onset to requiring a wheelchair for mobility (Delatycki et al., 1999b; Durr et al., 1996; Filla et al., 1996; Montermini et al., 1997b) .
The FXN GAA expansion is unstable in both meiosis and mitosis. The repeat can increase or decrease in size when passed from mother to child but generally decreases in size when passed from father to offspring (Delatycki et al., 1998; Monros et al., 1997) . Study of GAA size in the central nervous system identified evidence of mitotic repeat instability (Montermini et al., 1997a) . Somatic instability has been shown to be greater in heart and pancreas than in the central nervous system (Long et al., 2017) . Post-zygotic instability was shown to increase as people with FRDA get older (De Biase et al., 2007a,b; Long et al., 2017) .
There are no treatments proven to slow or reverse the neurodegeneration of FRDA (Tai et al., 2018) . Treatments are largely symptomatic for the wide range of morbidity seen in the condition (Corben et al., 2014) . There are an increasing number of clinical trials completed or underway. Increasingly, the agents being tested are rationally-designed and target pathways based on the understanding of how FXN mutations result in disease (Tai et al., 2018) .
Since the identification of the genetic basis of FRDA, much has been learned about the pathogenesis of this disorder. This has been through investigations of affected people as well as cell and animal models. This review will discuss the current state of knowledge in relation to the pathogenesis of FRDA and the implications for treating this disorder.
The expanded GAA repeat and FXN transcriptional deficiency
A key finding soon after the genetic cause of FRDA was discovered was that the expanded GAA repeat results in reduced quantities of normally spliced FXN transcript (Bidichandani et al., 1998) . Lymphoblast FXN transcript and frataxin protein levels in affected individuals were shown to be 5-30% of those in people who don't have FRDA (Campuzano et al., 1997; Chutake et al., 2014b) . A negative correlation exists between the length of GAA1 and levels of both FXN transcript and frataxin protein (Chutake et al., 2014b; Deutsch et al., 2010) . Thus, the primary molecular consequence of the expanded GAA repeat in FRDA is transcriptional deficiency of the FXN gene.
Transcriptional deficiency in FRDA is caused by various mechanisms, which together result in a combination of deficient FXN transcriptional initiation and elongation (Chutake et al., 2014a; Kim et al., 2011; Kumari et al., 2011; Li et al., 2015a; Punga and Buhler, 2010) . In FRDA, the FXN gene promoter is in a silenced state, and RNA polymerase II (pol II) is stalled upstream of the expanded GAA repeat.
The expanded GAA repeat is known to form non-canonical structures such as triplexes and triplex-based sticky DNA (Li et al., 2019; Sakamoto et al., 1999) . While it remains to be convincingly demonstrated that these particular structures form in vivo in the context of chromatin, the expanded GAA repeat stimulates the formation of an Rloop structure (DNA-RNA hybrid) in vivo (Groh et al., 2014) . The Rloop, which extends upstream of the expanded GAA repeat in intron 1, likely forms by interaction of the template DNA with the nascent transcript, or possibly via interaction with FAST-1, an antisense transcript detected in the same region (De Biase et al., 2009; Mikaeili et al., 2018) .
The expanded GAA repeat in FRDA results in the formation of repressive chromatin which is an important mediator of FXN transcriptional deficiency. That the expanded GAA repeat serves as a nidus for position effect variegation in mammalian cells (Saveliev et al., 2003) was the seminal finding that led to the exploration and identification of repressive chromatin in FRDA (Evans- Galea et al., 2012; Greene et al., 2007; Herman et al., 2006; Kumari et al., 2011) . Repressive chromatin spreads upstream from the expanded GAA repeat in intron 1 toward the FXN gene promoter (Chutake et al., 2014a) . Epigenetic silencing of human genes is commonly mediated by H3K9me3 or H3K27me3 form of repressive chromatin, acting via the HP1 or polycomb repressive pathways, respectively. The FXN gene is unusual in being silenced by both H3K9me3 and H3K27me3 (Yandim et al., 2013) . Histone hypoacetylation (H3K9, H3K4, H4K5), a hallmark of epigenetic silencing, also occurs in FRDA (Chutake et al., 2014a; Soragni et al., 2014) . Abnormal DNA methylation also occurs upstream of the expanded GAA repeat in FRDA, with evidence that it contributes to reduced gene expression (Castaldo et al., 2008; Evans-Galea et al., 2012) .
R-loops are known to mediate various regulatory processes, including the formation of repressive chromatin (Castellano-Pozo et al., 2013; Chedin, 2016; Chen et al., 2017; Santos-Pereira and Aguilera, 2015; Sanz et al., 2016) . The presence of the R-loop upstream of the expanded GAA repeat in FRDA may therefore serve as the pivotal mediator of both repressive chromatin leading to promoter insufficiency, and to the elongation block via stalling of pol II.
Therapeutic implications: Reactivation of the silenced FXN gene is an attractive therapeutic strategy. This is because the FXN coding sequence remains intact in the vast majority of people with FRDA, and while they have 5-30% levels of FXN transcript compared to individuals homozygous wildtype for FXN, heterozygous carriers with~50% level of FXN transcript remain asymptomatic. People with FRDA are typically homozygous for > 400 GAA triplets and have < 10% of FXN transcript compared to individuals homozygous wildtype for FXN. However, a substantial minority have at least one expanded GAA allele containing < 400 triplets and they have less severe FXN deficiency (10-30% of non-FRDA levels) (Chutake et al., 2014b) , a later age of onset (Delatycki et al., 1999b; Durr et al., 1996; Filla et al., 1996; Montermini et al., 1997b) and slower phenotypic progression (Regner et al., 2012) . These observations indicate that even a small improvement in the residual level of FXN transcript is likely to result in clinically meaningful outcomes. Since everyone so far identified with FRDA has at least one expanded GAA repeat, therapies designed to reverse FXN gene silencing caused by this mutation will be applicable to all affected individuals.
Various therapeutic strategies are being developed to target the molecular mediators of FXN gene silencing in FRDA. At least two classes of histone deacetylase (HDAC) inhibitors (2-aminobenzamide derivatives (Herman et al., 2006; Soragni et al., 2014) and nicotinamide (Libri et al., 2014) ) produce partial reactivation of the silenced FXN gene in FRDA via reversal of repressive chromatin. The 2-aminobenzamide derivative (HDACi-109), a class I HDAC inhibitor, also results in reactivation of the silenced FXN promoter (Chutake et al., 2016) . Another therapeutic strategy, employing oligonucleotides to disrupt R-loop formation, also showed partial reversal of FXN gene silencing (Li et al., 2016) . Dimethyl fumarate increases FXN transcript in FRDA with a concomitant reduction in R-loop formation (Jasoliya et al., 2019) . A synthetic transcription factor (syn-TEF1), designed to specifically reverse pol II stalling at the FXN locus, also showed partial FXN gene reactivation (Erwin et al., 2017) . Reactivation of the silenced FXN gene remains challenging because the use of any single modality of treatment tends to achieve partial correction, and when large enough cohorts are studied, considerable inter-individual variability in response is noted (Plasterer et al., 2013) .
Since everyone with FRDA has at least some residual FXN transcript, increasing the stability of the transcript is another feasible strategy to increase the levels of frataxin protein. Increasing translatability of the residual FXN transcript could also serve a similar role, and it has been suggested that the anti-HIV drug, etravirine, acts via this mechanism (Alfedi et al., 2019) .
With recent advances in genome editing, specifically deleting (or contracting) the expanded GAA repeat is another viable therapeutic avenue. In vitro studies in fibroblasts and iPS-derived neurons, and limited in vivo studies in a mouse model, have demonstrated that precise editing is feasible and that it reverses the transcriptionally deficient state (Lai et al., 2019; Li et al., 2015b; Ouellet et al., 2017) . However, in practice, such a strategy would likely face challenges relating to in vivo delivery, editing efficiency, and potential off-target effects.
Frataxin deficiency
The FXN gene encodes frataxin, a protein that is largely found in the mitochondria (Campuzano et al., 1997) . Frataxin is produced from the most abundant FXN transcript derived from exons 1-5a (Campuzano et al., 1996) . Frataxin is most highly expressed in dorsal root ganglia, the spinal cord, cerebellar dentate nuclei, cerebral cortex, pancreas, heart, liver and skeletal muscle (Campuzano et al., 1997 (Campuzano et al., , 1996 reflecting the main sites of pathology in FRDA (Koeppen, 2011) .
Frataxin is produced as a 210 amino acid polypeptide that undergoes cleavage to the final 130 amino acid mature protein by mitochondrial processing peptidase (Schmucker et al., 2008) . Cleavage of the N-terminal mitochondrial targeting sequence (MTS) between amino acids 41 and 42, produces an intermediate form, and between amino acids 80 and 81, results in the predominant mature form of frataxin (Condo et al., 2007) . Other isoforms of frataxin are produced and may be tissue specific (Xia et al., 2012) . A novel isoform of frataxin, isoform E, is present in erythrocytes which do not have mitochondria (Guo et al., 2018) . The role, if any, of isoform E in FRDA pathogenesis is unknown.
Frataxin is part of a complex that assembles iron-sulfur clusters (FeeS clusters) in the mitochondrial matrix (Fox et al., 2019; Muhlenhoff et al., 2002; Shan et al., 2007) . FeeS clusters are cofactors for proteins in the Krebs cycle (aconitase) and in mitochondrial respiratory complexes I, II, and III. Frataxin deficiency produces a secondary deficiency of these FeeS cluster containing proteins, which results in reduced mitochondrial ATP production. Frataxin also has other less well understood functions, for instance, involving iron metabolism/ transport/storage (Llorens et al., 2019) , heme synthesis (Bencze et al., 2007; Yoon and Cowan, 2004) , mitochondrial biogenesis (Jasoliya et al., 2017) , regulation of apoptosis (Wong et al., 1999) and in cellular antioxidant defense mechanisms (Shoichet et al., 2002) .
Mice that do not express frataxin succumb on embryonic day 6 confirming that it is an essential protein for survival as well as health (Cossee et al., 2000) . Indeed, no one has been identified who is homozygous for complete loss of function FXN alleles; that is, everyone with FRDA has at least some residual frataxin.
Therapeutic implications-Frataxin supplementation is being attempted either by direct delivery of frataxin protein (protein replacement therapy) (Britti et al., 2018; Vyas et al., 2012) or via delivery of a normal copy of the FXN gene via gene therapy (gene replacement therapy) (Gerard et al., 2014; Perdomini et al., 2014; Piguet et al., 2018) . Since everyone with FRDA has been exposed to at least some endogenous frataxin, immunogenicity to supplemental frataxin is unlikely to be a major concern. However, adequate targeting of key tissues, and appropriate subcellular processing and mitochondrial localization are important considerations. Gene therapy, which is reliant on the vector's predilection to efficiently target relevant tissues may be limited in its ability to target both peripheral tissues and those in the central nervous system. Treatment of a cardiac Fxn conditional knockout mouse model with intravenous delivery of an adeno-associated virus (AAV) vector not only prevented cardiomyopathy but was able to reverse established cardiac disease (Perdomini et al., 2014) .
Recovery of neurological function was demonstrated in a conditional
Fxn knockdown mouse model following restoration of gene function to normal levels (Chandran et al., 2017) . These animal studies provide hope that if frataxin levels are restored in key tissues of people with symptomatic FRDA, that in addition to cessation of disease progression, some reversal of symptoms may also be achieved. Gene therapy clinical trials using AAV vectors are expected to commence in the next 12 months.
Frataxin protein replacement has been attempted as a fusion of frataxin with the HIV trans-activator of transcription (TAT) domain. The TAT domain, used to efficiently penetrate cellular membranes, resulted in efficient delivery of frataxin to mitochondria via intraperitoneal injection, and produced significant improvement in the phenotype of a FRDA knockout mouse model (Vyas et al., 2012) . Frataxin has an unusually long MTS that undergoes two separate cleavage events during mitochondrial import. Others have redesigned the TATfrataxin fusion protein by replacing the long endogenous MTS with a shorter one from citrate synthase as an attempt to further improve mitochondrial targeting (Britti et al., 2018) .
In addition to the molecules that increase frataxin production via increasing FXN gene expression, several compounds (e.g. erythropoietin, interferon gamma, resveratrol, diazoxide and methylene blue) increase cellular levels of frataxin without a commensurate increase in the level of FXN transcript (Khdour et al., 2018; Li et al., 2013; Santoro et al., 2018; Sturm et al., 2005; Tomassini et al., 2012) . In many cases the mechanism of action remains unknown. In general, these compounds produce small increases in the level of frataxin, which is not comparable to the level of frataxin achievable (and likely necessary for clinical improvement) via protein or gene replacement therapy.
There is some evidence that FeeS cluster biogenesis may be possible in a frataxin-deficient state. For instance, hypoxia rescues FeeS cluster biogenesis in the frataxin-deficient environment (Ast et al., 2019) . This finding is supported by work in a C.elegans model where mitochondrial autophagy was identified in the presence of frataxin deficiency (Schiavi et al., 2015) . This was seen as a hypoxia like, iron starvation protective response raising a possible pathway to investigate for therapeutic development for FRDA. A yeast mutation involving the scaffold protein (Isc1) on which FeeS clusters are synthesized, a process that is normally catalyzed by frataxin, was shown to effectively bypass the need for frataxin (Yoon et al., 2015) . These observations suggest alternate possibilities to make up for the loss of frataxin. Perhaps, small molecule frataxin mimetics could be identified (or designed) as surrogates to enhance FeeS cluster biogenesis. It should be noted, however, that while FeeS cluster biogenesis is perhaps the best characterized function of frataxin, simply correcting this dysfunction may leave other outcomes of frataxin deficiency uncorrected.
Iron and Friedreich ataxia
In a landmark study, Babcock and colleagues reported that yeast with deletion of the yeast homolog of FXN (Yfh1) had markedly increased mitochondrial iron (Babcock et al., 1997) . Fibroblasts from people with FRDA have higher mitochondrial iron that fibroblasts from control individuals (Delatycki et al., 1999a) . The identification of cardiac iron deposition in post mortem hearts from individuals with FRDA prior to the discovery of the genetic basis of the disorder was subsequently rediscovered (Lamarche et al., 1993; Sanchez-Casis et al., 1976) . There is also imaging data showing excess iron in the dentate nuclei of the cerebellum, a major site of pathology in FRDA, and that levels of iron increase with disease progression (Waldvogel et al., 1999; Ward et al., 2019) . Yeast studies suggest that excess mitochondrial iron is the result of reduced efflux rather than increased influx (Radisky et al., 1999) . Upregulation of mitoferrin in frataxin deficient flies was identified as the mechanism for excess mitochondrial iron uptake and downregulation of mitoferrin protected the flies from consequences of frataxin deficiency (Navarro et al., 2015) .
Studies in drosophila (Chen et al., 2016b) and mouse (Chen et al., 2016a) FRDA models have identified that increased mitochondrial iron results in increased sphingolipid synthesis and activation of Pdk1 and Mef2 leading to neurodegeneration. Reduced iron toxicity, reduction of sphingolipids by myriocin and reduction of Pdk1 and Mef2 all led to reduced neurodegeneration. The finding of increased sphingolipids and PDK1 in hearts of people affected by FRDA support the premise that the animal findings are also true for human FRDA (Chen et al., 2016a) . These data identify a role for the activation of the iron/sphingolipid/ Pdk1/Mef2 pathway in the pathogenesis of FRDA however these findings were not replicated in another mouse model of FRDA (Chandran et al., 2017) .
Ferroptosis is regulated iron-dependent cell death that is independent of apoptosis. Evidence for ferroptotic pathway activation was found in cell models of FRDA (Cotticelli et al., 2019) . Ferroptosis inhibitors protected these cell models exposed to ferric ammonium citrate (FAC) and buthionine sulfoximine (BSO). A potential therapeutic role for ferroptosis inhibitors in FRDA is therefore suggested by these data.
Therapeutic implications-The finding of increased mitochondrial iron has led to studies of iron chelators in FRDA. Deferoxamine has characteristics that make it unlikely to be of therapeutic value in FRDA including inability to cross the blood brain barrier and its high affinity for iron (Alsina et al., 2018) . Deferiprone was tested in a placebocontrolled study (Pandolfo et al., 2014) . Whilst some improvement in cardiac parameters was found in those treated with 20 mg/kg/day and 40 mg/kg/day, those treated with 40 mg/kg/day deferiprone had significantly greater worsening of scores on an ataxia rating scale compared to those treated with placebo. The 60 mg/kg/day group was discontinued due to worsening of ataxia in two individuals. The failure of iron chelation in clinical trials may be due to the fact that there is not total body iron overload in FRDA as evidenced by normal iron indices in those with this disorder (Wilson et al., 1998) . Thus an agent that can relocate iron from the mitochondria to the cytosol may be required rather than iron chelators that remove iron from the body (Pandolfo and Hausmann, 2013) .
Oxidative stress
The first data that raised the possibility of oxidative stress being implicated in the pathogenesis of FRDA was the finding of increased mitochondrial iron in cellular models and cell lines from people with FRDA (Babcock et al., 1997; Delatycki et al., 1999a) . Free iron in mitochondria results in the generation of reactive oxygen species by Fenton chemistry (Armstrong et al., 2010) .
In a mouse model of FRDA with homozygous GAA expansions, increased levels of oxidized proteins and malondialdehyde were identified in the central nervous system along with reduced aconitase levels (Al-Mahdawi et al., 2006) . Another mouse model study revealed increased reactive oxygen species generation in the mitochondrial matrix and cytosol resulting in glutathione depletion and excess lipid peroxidation (Abeti et al., 2016) . A Drosophila model of frataxin deficiency was found to have an increase in fatty acids leading to increased lipid peroxidation and knockdown of frataxin in glial cells that led to lipid accumulation (Navarro et al., 2010) . Co-expression of an apolipoprotein D ortholog protected the fly model mainly by controlling lipid peroxidation. Frataxin interacts with and increases levels of SOD1 indicating a role of SOD1 in frataxin-related antioxidant activity (Han et al., 2019) .
The role of oxidative stress in the pathogenesis of FRDA was brought into question by a mouse study where treatment with a MnSOD mimetic, MnTBAP, or overexpression of Cu,ZnSOD did not improve the cardiac phenotype in a cardiac Fxn conditional knockout model (Seznec et al., 2005) . This was supported by the observation of no increase in reactive oxygen species in the neuronal region in frataxin deficient Drosophila larvae (Shidara and Hollenbeck, 2010) . In addition increase in antioxidant defences have been largely unsuccessful in rescuing the phenotype in frataxin deficient flies (Chen et al., 2016b; Edenharter et al., 2018; Tricoire et al., 2014) . A more recent study of mouse fibroblasts with conditional knockout of Fxn revealed the first event after the gene was knocked out was reduced aconitase, with subsequent increased reactive oxygen species, and mitochondrial iron accumulation occurring last (Poburski et al., 2016) . The authors of that study concluded that impaired FeeS cluster synthesis is the primary event in the pathogenesis of FRDA whilst increased oxidative stress and iron accumulation are secondary.
In vivo studies in humans have provided mixed results. Urinary 8hydroxyl-2`deoxyguanosine levels (8OH2´dG), a marker of oxidative damage, was found to be 2.6 times higher in people with FRDA than controls and levels were significantly reduced by treatment with 5 mg/ kg/day of idebenone (Schulz et al., 2000) . In contrast, in a placebocontrolled trial of a range of doses of idebenone, 8OH2´dG levels were not found to be elevated and they were not impacted by idebenone treatment (Di Prospero et al., 2007a) . In an open label study of resveratrol, significant improvement in plasma F 2 -isoprostanes, a marker of oxidative stress, was observed (Yiu et al., 2015) .
Nuclear factor erythroid-derived 2-related 2 (Nrf2) function has been shown to be deficient in FRDA (Paupe et al., 2009) . This is proposed to impact fatty acid oxidation and ATP production and result in oxidative stress.
Therapeutic implications-There have been a number of studies of antioxidants in FRDA. Idebenone has been tested in a number of clinical trials (Di Prospero et al., 2007a,b; Lynch et al., 2010; Schols et al., 2001) . Despite early optimism about its efficacy in particular for cardiac impact in FRDA, idebenone has not been proven to be efficacious for treating this disorder. Other antioxidants tested in clinical trials include vitamin E and coenzyme Q 10 (Cooper et al., 2008) , A0001 (Lynch et al., 2012) and EPI-743 (Zesiewicz et al., 2018) . RTA408 (omaveloxolone) is an Nrf2 activator. It has shown promise as a treatment for FRDA in a dose finding study (Lynch et al., 2019) and is currently being tested in a 12 month placebo-controlled trial (www. clinicaltrials.gov).
Inflammation in FRDA
There are a number of lines of evidence for inflammation playing a role in the pathogenesis of FRDA. Inflammation has been identified in animal models (Shen et al., 2016) and tissues from people with FRDA (Koeppen et al., 2016) . A peripheral blood transcriptome study identified a transcriptional signature enriched for an inflammatory innate immune response in those with FRDA compared to individuals heterozygous for a FXN GAA expansion and non-FRDA controls (Nachun et al., 2018) . Treatment of a FRDA mouse model with granulocytecolony stimulating factor (G-CSF) and stem cell factor (SCF) resulted in improved motor coordination and reduced inflammation and gliosis (Kemp et al., 2017) . A suggestion that neurological symptoms are improved with corticosteroid treatment came from observation of an individual with FRDA and nephrotic syndrome and a subsequent review of patient records of individuals with FRDA treated with corticosteroids for a variety of indications (Shinnick et al., 2016) .
Therapeutic implications -An 26-week open label trial of pulse methylprednisolone in 11 individuals with FRDA did not identify a significant improvement in the primary outcome measure, the 25-ft walk test (Patel et al., 2019) . There was significant improvement in the 1-min timed walk.
How do other mutations impact the pathogenesis of FRDA?
Individuals who are compound heterozygous for a FXN GAA expansion and a different pathogenic mutation in the other allele may have differences in phenotype to those homozygous for a GAA expansion (Galea et al., 2016) . Those with a null mutation in addition to a GAA expansion have, on average, an earlier age of onset and are more likely to have diabetes mellitus than those homozygous for a GAA expansion. This is consistent with the lower amount of residual frataxin in such individuals. Some point mutations such as p.Gly130Val can result in minimal upper limb involvement and dysarthria but severe lower limb spasticity (Bidichandani et al., 1997; Caron et al., 2015; McCabe et al., 2002) . The p.Gly130Val mutation does not affect FXN transcript levels and is predicted to have minimal impact on protein stability (Galea et al., 2016) . This can explain the milder phenotype that it is associated with this mutation but doesn't explain the differing impact on lower compared to upper body regions.
Other observations that impact understanding of FRDA pathogenesis
Study of an Arabidopsis model with a GAA expansion in the IIL1 gene that results in a temperature dependent phenotype has shown that there is accumulation of 24-nucleotide short interfering RNAs (siRNAs) and repressive marks at the locus (Eimer et al., 2018) . This results in transcriptional downregulation of IIL1 and the phenotype seen in the plants. Knocking down components of the RNA-dependent DNA methylation (RdDM) pathway suppressed both transcriptional downregulation of IIL1 and the repeat expansion-associated phenotype. The authors of that study postulate that siRNAs may be involved in the pathogenesis of FRDA and therapies that interfere with siRNAs may be beneficial in this condition.
Micro RNAs (miRNAs) are small non-coding RNAs that are involved in gene expression. Twenty differentially regulated miRNAs were identified in plasma of people with FRDA compared to control individuals (Dantham et al., 2018) . Seventeen were upregulated while three were downregulated.
In addition to the role of iron in the pathogenesis of FRDA, a number of other metals have been implicated. Induced pluripotent stem cells from individuals with FRDA differentiated into cardiomyocytes were found to have increased variation of beating rate compared to those derived from people without FRDA (Crombie et al., 2017) . This variation was prevented by nifedipine suggesting a calcium handling deficiency. Reduced calcium was identified in FXN deficient sensory neurons and this was restored by treatment with phosphodiesterase (PDE) inhibitors (Molla et al., 2019) . In vitro PDE inhibitor treatment of DRG neurons from a FRDA mouse model reverted axonal dystrophy. In another study, copper was found to be lower in cardiac tissue from people with FRDA than in cardiac tissue from people without the condition (Kruger et al., 2016) . The authors of that study postulated that copper therapy may be beneficial as a therapy for FRDA cardiomyopathy. Increased levels of zinc, copper, manganese and aluminium were identified in a Drosophila model of FRDA in addition to increased iron (Soriano et al., 2016) . Treatment with copper and zinc chelators resulted in improved motor performance.
A number of polymorphisms have been shown to impact FRDA phenotype. The presence of HFE p.Cys282Tyr was shown to be associated with an earlier age of FRDA disease onset (Delatycki et al., 2014) . This was postulated to relate to the role of the HFE variant in iron metabolism. The rs5186 polymorphism in AGTR1 was shown to be associated with cardiac hypertrophy in individuals with FRDA (Kelly et al., 2011) . Application of genome wide association study (GWAS), successfully applied to other neurogenetic disorders, has the potential to identify other genetic modifiers in FRDA (Moss et al., 2017) .
Reduced mitochondrial biogenesis has been identified in those with FRDA (Jasoliya et al., 2017) . This is thought to be secondary to frataxin deficiency.
Potential developmental effects of frataxin deficiency
Given that frataxin is essential for early embryonic development (Cossee et al., 2000) , it is conceivable that frataxin deficiency could result in some adverse developmental effects that may not be reversible via postnatal frataxin restoration. Postnatal frataxin restoration via gene therapy, protein replacement, or restitution of FXN expression has shown remarkable effectiveness, however these studies have typically been conducted in mouse models that were generated by postnatal (and often tissue-specific) induction of frataxin deficiency (Chandran et al., 2017; Perdomini et al., 2014; Vyas et al., 2012) . Since these models developed in a frataxin replete environment, they are not equivalent to the human condition. Unfortunately, the two mouse models that mimic the human condition in having frataxin deficiency throughout life, KIKO (Lin et al., 2017; McMackin et al., 2017) and YG8sR (Anjomani Virmouni et al., 2015) , have a subtle phenotype on account of having short GAA repeats and are therefore less than ideal for addressing this question. A version of the YG8sR mouse with long repeats, similar to those in most people with FRDA, has recently been developed and may help to address this question.
Conclusion
Since the identification of mutations in FXN as the cause of FRDA, there has been considerable progress in the understanding of the pathogenesis of this disorder. This has led to identification of potential therapies with multiple clinical trials completed, underway and planned. There remain, however, areas of uncertainty and much that is still to be learned from further study of people with FRDA, and in cell and animal models. There is much reason for optimism that treatments that will at least slow the progression of FRDA, and hopefully even reverse some symptoms, will be available in the clinic in the near future.
